{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T03:11:03Z","timestamp":1648696263027},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n          Prinzip des therapeutischen Drug Monitorings\u2002F\u00fcr immer mehr Antiinfektiva gibt es Erkenntnisse zur Expositions-Wirkungs-Beziehung, die im therapeutischen Drug Monitoring (TDM) genutzt werden k\u00f6nnen. Dabei spielt die Sch\u00e4tzung der AUC (area under the curve) eine wichtige Rolle. Eine spezielle Pharmakokinetik-Software hilft in der Praxis, die Sch\u00e4tzung der AUC auch anhand weniger Proben zu erm\u00f6glichen.<\/jats:p><jats:p>\n          F\u00fcr welche Arzneistoffe wird ein therapeutisches Drug Monitoring empfohlen?\u2002Neben dem vielfach bereits etablierten TDM\u200af\u00fcr Aminoglykoside (Amikacin, Gentamicin und Tobramycin) und Glykopeptide (Vancomycin, Teicoplanin) empfiehlt ein fach\u00fcbergreifendes Expertengremium bei Intensivpatienten ein TDM\u200af\u00fcr Betalaktame, Linezolid und Voriconazol. Neuerungen gibt es auch bei Vancomycin, bei dem vom h\u00e4ufig praktizierten \u201eTalspiegel\u201c-TDM\u200azum in klinischen Studien \u00fcberlegenen AUC-basierten TDM\u200a\u00fcbergegangen werden soll.<\/jats:p>","DOI":"10.1055\/a-1207-1914","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T18:48:40Z","timestamp":1606762120000},"page":"1764-1769","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutisches Drug Monitoring von Antiinfektiva bei\u00a0Intensivpatienten \u2013 f\u00fcr welche Arzneistoffe und wie?"],"prefix":"10.1055","volume":"145","author":[{"given":"Christina","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf, Klinik\u00a0f\u00fcr\u00a0Intensivmedizin"},{"name":"Universit\u00e4tsklinikum Hamburg- Eppendorf, Klinikapotheke"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf, Klinik\u00a0f\u00fcr\u00a0Intensivmedizin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian G.","family":"Wicha","sequence":"additional","affiliation":[{"name":"Universit\u00e4t Hamburg, Institut f\u00fcr Pharmazie, Abt.\u00a0Klinische\u00a0Pharmazie"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"M H Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"J A Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"ref3","first-page":"R206","article-title":"Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of \u03b2-lactams","volume":"15","author":"J Gon\u00e7alves-Pereira","year":"2011","journal-title":"Crit\u00a0Care"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1093\/jac\/dky314","article-title":"Therapeutic drug monitoring of \u03b2-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures","volume":"73","author":"G Wong","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/pharmaceutics9030036","article-title":"Augmented Renal Clearance in Critical Illness: An Important Consideration in Drug Dosing","volume":"9","author":"S Mahmoud","year":"2017","journal-title":"Pharmaceutics"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5301\/ijao.5000377","article-title":"Anti-Infective Drugs during Continuous Hemodialysis -Using the Bench to Learn What to do at the Bedside","volume":"38","author":"A C Roehr","year":"2015","journal-title":"Int J Artif Organs"},{"key":"ref7","first-page":"444","article-title":"Pharmacotherapy and kidney dysfunction","volume":"114","author":"F Keller","year":"2019","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of \u03b2-lactams, glycopeptides, and linezolid","volume":"17","author":"W Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014","volume":"37","author":"L M Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijantimicag.2014.12.010","article-title":"TDMx: A novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine","volume":"45","author":"S G Wicha","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40262-018-0707-9","article-title":"Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?","volume":"58","author":"Y Gao","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1093\/jac\/dkaa320","article-title":"Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure","volume":"75","author":"R V Shingde","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijantimicag.2017.11.009","article-title":"Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial","volume":"51","author":"S De Winter","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e02042-17","DOI":"10.1128\/AAC.02042-17","article-title":"A prospective trial on the use of trough concentration versus area under the curve (AUC) to determine therapeutic vancomycin dosing","volume":"62","author":"M N Neely","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by\u00a0the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatr","volume":"77","author":"M J Rybak","year":"2020","journal-title":"Am J Heal Pharm"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/IDR.S146961","article-title":"Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in chinese patients with moderate-severe gram-positive infections","volume":"11","author":"L Zhou","year":"2018","journal-title":"Infect Drug Resist"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use Programme","volume":"42","author":"C R Rayner","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12185-009-0296-3","article-title":"Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders","volume":"89","author":"K Ueda","year":"2009","journal-title":"Int J Hematol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients","volume":"55","author":"P F Troke","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1207-1914.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T18:49:22Z","timestamp":1606762162000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1207-1914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":19,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2020,11,30]]},"published-print":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1207-1914","relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]}}}